Patients & Caregivers

Articles

FDA Grants Breakthrough Therapy Designation For Genentech’s Alecensa ®

Genentech, a member of the Roche Group, announced on October 3, 2016 that it has received a second Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for its anaplastic lymphoma kinase (ALK) inhibitor, Alecensa (alectinib)... FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR GENENTECH’S ALECENSA® (ALECTINIB) FOR FIRST-LINE TREATMENT OF PEOPLE WITH ALK-POSITIVE NSCLC – This Second Alecensa Breakthrough Therapy Designation Was Granted Based on Phase III J-ALEX Study  – SOUTH SAN FRANCISCO, Calif. – October 3, 2016 –Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it has received a second Breakthrough Therapy Designation ...
Read More

Ten Essential Facts about Lung Cancer

Did you know that lung cancer is the leading cause of cancer deaths in the U.S. but is the least funded? Read more essential facts about lung cancer in this presentation and learn what you can to help in raising funds and awareness with the Lung Cancer Research Council.   ...
Read More

Genentech’s cancer immunotherapy TECENTRIQTM (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy

The latest news on Genentech's immunotherapy molecule Tecentriq (atezolizumab) for NSCLC: Genetech’s Phase III Study, OAK, helped people with a specific type of lung cancer live significantly longer compared to chemotherapy, demonstrating significant improvement in OS for people regardless of their PD-L1 status. PHASE III STUDY SHOWED GENENTECH’S CANCER IMMUNOTHERAPY TECENTRIQTM (ATEZOLIZUMAB) HELPED PEOPLE WITH A SPECIFIC TYPE OF LUNG CANCER LIVE SIGNIFICANTLY LONGER COMPARED TO CHEMOTHERAPY – TECENTRIQ showed significant improvement in overall survival for people regardless of their PD-L1 status – – Data will be discussed with global health authorities, including the U.S. Food and Drug Administration (FDA) – SOUTH SAN FRANCISCO, ...
Read More

Immunotherapy and its Ability to Fight Cancer

Unlike chemotherapy that attacks cancer directly, immunotherapy leverages a patient’s own immune system to help battle disease. Learn more about how immunotherapy helped a lung cancer patient restore his health and more in this New York Times article by Denise Grady. (more...) ...
Read More

General Cancer – Punta Gorda Ladies’ Support Group

Celebrate Life: Ladies’ Cancer Support Group 1st Wednesday of every month 10 a.m. Punta Gorda Isles Civic Association 2001 Shreve Street Punta Gorda, FL 33950 Further information: Contact Diane Mebey: 941-575-7746 Contact Sara Benson: 941-575-6765 saraben918@earthlink.net http://www.pgica.org/clubs/celebrateLife.htm ...
Read More

New NCCN Guidelines for Patients

The National Comprehensive Cancer Network has recently published their NCCN Guidelines for Patients for Non-Small Cell Lung Cancer. The Lung Cancer Research Council has endorsed and is a sponsor of this guide! It includes a wealth of information for patients, especially those newly diagnosed. It is the mission of the Lung Cancer Research Council to increase public awareness and understanding about lung cancer. We support programs for screening and early detection. We are thrilled to be able to promote this guide! Web manual: www.nccn.org/patients/guidelines/nscl/index.html Web page (with other manuals): www.nccn.org/patients/guidelines/cancers.aspx#nsclc   ...
Read More

Madisen’s Match! Purchase tickets by Sept. 18, 2015

Purchase raffle tickets by September 18, 2015 for a chance to win free tickets to a Taylor Swift Concert - Support The Golisano Children's Hospital and enter a chance drawing to win 4 Tickets to see Taylor Swift at Raymond James Stadium in Tampa, FL, on October 31st, 2015. For more information, click here. All proceeds go directly to The Golisano Children's Hospital Cancer Center Fund, and The Brain Tumor Navigator Program at The Regional Cancer Center of the Lee Memorial Health System Foundation, serving Charlotte and Lee Counties and beyond ...
Read More

Don’t Live with Lung Cancer Alone

written by Irene, local lung cancer survivor Many people attend a Support Group seeking encouragement and hope. And then later are the ones offering encouragement and hope to someone else. A study in 1989 by Dr. Spiegel published results that showed women with advanced breast cancer who received one year of weekly psychosocial support, along with standard care, lived an average of 18 months longer - twice as long as did members of the control group who received only standard care. Following this work, Dr. Spiegel and other researchers have continued to produce evidence that psychosocial support not only improves quality of life but may ...
Read More

What Would Lung Cancer Screening Mean to You and Your Family?

The United States Preventive Services Task Force released draft recommendations for annual low-dose CT screening for individuals at high risk for lung cancer. Who is considered high risk? Current and former smokers, ages 55–79 years, who have significant cumulative tobacco smoke exposure and have smoked within the last 15 years. If these recommendations are enacted, lung cancer screening would be free for those patients in the high risk group. This would be a great step in the right direction. Low dose CT screening for lung cancer has been shown to reduce lung cancer mortality by up to 14%. Read More

General Resources